Healthcare stakeholders suggest system changes, proving therapeutic value.
In a study published by the BMJ, results say that although a significant number of drugs are receiving approval in the US and Europe, less than half are offering therapeutic value to patients. Examining a group of 124 first indications between 2011 and 2020, 47% in Europe and 41% in the US received high therapeutic value ratings. The authors concluded that information should be clearly communicated to patients and be reflected in the drug pricing when therapeutic value is not added over other available treatments. Healthcare stakeholders further suggested all medications must be required to provide therapeutic value in order to receive approval.
Relying on therapeutic value ratings from European health technology assessment (HTA) groups, the study acknowledged that ratings were not available in the US. Currently, the US doesn’t employ the HTA system frequently.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.